null Thomas Mavrakanas, MD, M.Sc.
chronic kidney disease • kidney failure • cardiovascular disease • anticoagulation • cardiorenal syndromes • coronary disease
My research focuses on the causes of and treatments for cardiovascular disease in patients with chronic kidney disease (CKD) and kidney failure. I have significant expertise in designing pharmacokinetic or observational studies and using large administrative datasets. I was also the first scientist to study the pharmacokinetics of apixaban, a direct oral anticoagulant, at steady state in patients on maintenance dialysis. My work aims to optimize management of patients with chronic kidney and cardiovascular disease in order to prevent occurrence of myocardial infarction, stroke, or admission for heart failure, as well as to slow down CKD progression to kidney failure.
Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol 2020; 15(8): 1146-1154. PMID: 32444398.
Mavrakanas TA, Samer CF, Nessim S, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28(7): 2241-2248. PMID: 28302754.
Mavrakanas TA, Khattak A, Singh K, Charytan DM. Epidemiology and natural history of the cardiorenal syndromes in a cohort with echocardiography. Clin J Am Soc Nephrol 2017; 12(10): 1624-1633. PMID: 28801528.
Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol 2019; 14(6): 810-822. PMID: 31010936.
Mavrakanas TA, Giannetti N, Sapir-Pichhadze R, Alam A. Mineralocorticoid receptor antagonists and renal outcomes in heart failure patients with and without chronic kidney disease. CardioRenal Medicine 2020; 10(1): 32-41. PMID: 31665724.